A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

Inclusion Criteria Concurrent Medication: Allowed: * Chemoprophylaxis for Pneumocystis carinii, candida, and mycobacteria. * Acyclovir for acute treatment of herpes. Exclusion Criteria Concurrent Medication: Excluded: * Antiretroviral agents, including ddI, ddC, AZT, and d4T. * Immunosuppressive agents. * Investigational HIV drugs/therapies including vaccines. * Interferon or other immunomodulating agents. * Corticosteroids (other than topical). * Megestrol acetate. * Agents known to cause neutropenia. * Ganciclovir. * Cytotoxic chemotherapy. Concurrent Treatment: Excluded: * Radiation therapy. Patients with the following prior conditions are excluded: * Poor compliance (less than 80 percent of drug taken) on the Phase I protocol (FDA 234A or FDA 234B). * Missed more than one clinic visit on the Phase I protocol. Prior Medication: Excluded: * Acyclovir as prophylaxis for herpes within 48 hours prior to study entry. Patients meet the following criteria: Successful completion of short-term therapy with vesnarinone on FDA 234A or FDA 234B. Active illicit drug abuse.